Sensitive and cost-effective LC-MS/MS method for quantitation of CVT-6883 in human urine using sodium dodecylbenzenesulfonate additive to eliminate adsorptive losses

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 10, 2009, Pages 943-947

  Chen, Chungwen ^a   Bajpai, Lakshmikant ^a   Mollova, Nevena ^a   Leung, Kwan ^a  

^a CV THERAPEUTICS INC   (United States)

Author keywords

A2B adenosin receptor antagonist; Adsorptive losses; CVT 6883; Human urine; LC MS MS; Method validation; Non specific binding; SDBS; Sodium dodecylbenzenesulfonate

Indexed keywords

BODY FLUIDS; CAPILLARY TUBES; COST BENEFIT ANALYSIS; COST EFFECTIVENESS; RECOVERY; REFRIGERATION; SODIUM; TEMPERATURE;

A2B ADENOSIN RECEPTOR ANTAGONIST; ADSORPTIVE LOSSES; CVT-6883; HUMAN URINE; LC-MS/MS; METHOD VALIDATION; NON-SPECIFIC BINDING; SDBS; SODIUM DODECYLBENZENESULFONATE;

VARIABLE SPEED TRANSMISSIONS;

3 [(3 CHOLAMIDOPROPYL)DIMETHYLAMMONIO] 1 PROPANESULFONIC ACID; 3 ETHYL 1 PROPYL 8 [1 (3 TRIFLUOROMETHYLBENZYL) 1H PYRAZOL 4 YL] 3,7 DIHYDROPURINE 2,6 DIONE; ACETONITRILE; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR ANTAGONIST; BOVINE SERUM ALBUMIN; CVT 6883; DIMETHYL SULFOXIDE; DODECYL SULFATE SODIUM; DODECYLBENZENESULFONATE SODIUM; DRUG ADDITIVE; HYDROCHLORIC ACID; LABRASOL; METHANOL; N,N DIMETHYLACETAMIDE; POLYSORBATE 80; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ADSORPTION; DRUG STABILITY; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

ADSORPTION; BENZENESULFONATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; PURINES; PYRAZOLES; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

EID: 62249114120     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.02.045     Document Type: Article

References (10)

1. Sun C.-X., Zhong H., Mohsenin A., Morschl E., Chunn J.L., Molina J.G., Belardinelli L., Zeng D., and Blackburn M.R. J. Clin. Invest. 116 (2006) 2173
2. Schwartz M., Kline W., and Matuszewski B. Anal. Chim. Acta 352 (1997) 299
3. Fisher A.L., DePuy E., Shih T., Stearns R., Lee Y., Gottesdiener K., Flattery S., De Smet M., Keymeulen B., and Musson D.G. J. Pharm. Biomed. Anal. 26 (2001) 739
4. Groff M., Riffel K., Song H., and Lo M.-W. J. Chromatogr. B 842 (2006) 122
5. Xu Y., Du L., Rose M.J., Fu I., Woolf E.J., and Musson D.G. J. Chromatogr. B 818 (2005) 241
6. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001. http://www.fda.gov/cder/guidance/4252fnl.htm.
7. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., and Weiner R. AAPS J. 9 (2007) E30 (Article 4)
8. Bansal S., and DeStefano A. AAPS J. 9 (2007) E109 (Article 11)
9. Nowatzke W., and Woolf E. AAPS J. 9 (2007) E117 (Article 13)
10. Xu X., Mei H., Wang S., Zhou Q., Wang G., Broske L., Pena A., and Korfmacher W.A. Rapid Commun. Mass Spectrom. 19 (2005) 2643